NeuroBo Pharmaceuticals, Inc. (NRBO)

NASDAQ: NRBO · IEX Real-Time Price · USD
0.399
-0.001 (-0.23%)
At close: Aug 12, 2022 4:00 PM
0.390
-0.009 (-2.280%)
After-hours: Aug 12, 2022 6:59 PM EDT
-0.23%
Market Cap 10.64M
Revenue (ttm) n/a
Net Income (ttm) -14.84M
Shares Out 26.66M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 40,914
Open 0.400
Previous Close 0.400
Day's Range 0.390 - 0.401
52-Week Range 0.340 - 4.950
Beta -0.47
Analysts Buy
Price Target 16.32 (+3,989.2%)
Earnings Date Aug 15, 2022

About NRBO

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Ge... [Read more...]

Industry Biotechnology
Employees 5
Stock Exchange NASDAQ
Ticker Symbol NRBO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for NRBO stock is "Buy." The 12-month stock price forecast is 16.32, which is an increase of 3,989.20% from the latest price.

Price Target
$16.32
(3,989.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NeuroBo Pharmaceuticals, Inc. Expands Management Team with the Appointment of Matthew Bardin, PharmD, BCPS as Senior ...

BOSTON , May 6, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment, effective April 30, 2022 of Matthew Bardin, Ph...

NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results

BOSTON , April 1, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced financial results for the year ended December 31, 2021. Manag...

NeuroBo Pharmaceuticals, Inc. Expands Scientific Advisory Board with Appointment of Danamarie Belpulsi, M.D.

BOSTON, March 15, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment, effective immediately, of Danamarie Belpulsi...

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

BOSTON, Jan. 28, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Direct...

10 Low-Float Penny Stocks for Steel-Gutted Investors

If you're willing to absorb massive risk for the chance of significant upside, these low-float penny stocks could fit the bill. The post 10 Low-Float Penny Stocks for Steel-Gutted Investors appeared fir...

NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results

BOSTON, Nov. 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapie...

NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer

BOSTON, Nov. 4, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies...

Hot Penny Stocks: Why NEW, ARDX, WTRH, GSAT and NRBO Are Moving Today

There's loads of hot penny stocks worth checking in on today and we're taking a look at what some of the top movers are doing! The post Hot Penny Stocks: Why NEW, ARDX, WTRH, GSAT and NRBO Are Moving To...

Other symbols: ARDXBBGSATWTRH

NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase ...

BOSTON, Oct. 13, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapie...

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapie...

NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering

BOSTON, Oct. 1, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapie...

7 Biotech Stocks to Buy That Have Millionaire-Maker Potential

This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.

Other symbols: AVIRHSTONVIVPRVBSYNSQL

NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results

BOSTON, Aug. 16, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapie...

NRBO Stock: 6 Things to Know About NeuroBo Pharma as Retail Investors Send Shares Rocketing

Neurobo Pharmaceuticals (NRBO) stock is on the rise Tuesday as retail traders take a liking to the biotechnology company. The post NRBO Stock: 6 Things to Know About NeuroBo Pharma as Retail Investors S...

NeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors

BOSTON, July 12, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapie...

NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results

BOSTON, May 17, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies...

NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update

BOSTON, April 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapi...

NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene

BOSTON, March 24, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has received approval of an amendment to its Continge...

NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement

BOSTON, Jan. 21, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced private placement of a...

NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program

BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a priva...

NeuroBo Pharmaceuticals (NRBO) Surges: Stock Moves 5.2% Higher

NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results

BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...

NeuroBo Pharmaceuticals Reports Second Quarter 2020 Financial Results

BOSTON, Aug. 11, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes

BOSTON, June 16, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...